Amended Statement of Ownership (sc 13g/a)
January 15 2021 - 3:43PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 6)*
Enzo
Biochem, Inc.
(Name of Issuer)
Common Stock, $0.01 Par Value
(Title of Class of Securities)
294100102
(CUSIP Number)
December 31, 2020
(Date of Event Which Requires Filing of
this Statement)
Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:
x
Rule 13d-1(b)
¨
Rule 13d-1(c)
¨
Rule 13d-1(d)
_____________________________
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required
in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
CUSIP NO. 294100102
|
13G
|
Page 2 of 7 Pages
|
1
|
NAME OF REPORTING PERSON
Evermore Global Advisors, LLC
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ¨
(b) ¨
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
2,605,607 (See Item 4)
|
6
|
SHARED VOTING POWER
0 (See Item 4)
|
7
|
SOLE DISPOSITIVE POWER
2,605,607 (See Item 4)
|
8
|
SHARED DISPOSITIVE POWER
0 (See Item 4)
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,605,607
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see
instructions)
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 91
5.4%
|
12
|
TYPE OF REPORTING PERSON
(see instructions)
IA
|
1
This percentage is based on 47,895,050 shares of common stock outstanding as of December 1, 2020, as set forth in
the Issuer’s Form 10-Q for the quarter ended October 31, 2020.
CUSIP NO. 294100102
|
13G
|
Page 3 of 7 Pages
|
1
|
NAME OF REPORTING PERSON
Evermore Global Value Fund, a series of Evermore Funds Trust
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) ¨
(b) ¨
|
3
|
SEC USE ONLY
|
4
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Massachusetts
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
5
|
SOLE VOTING POWER
02 (See Item 4)
|
6
|
SHARED VOTING POWER
0 (See Item 4)
|
7
|
SOLE DISPOSITIVE POWER
02 (See Item 4)
|
8
|
SHARED DISPOSITIVE POWER
0 (See Item 4)
|
9
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,605,607
|
10
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see
instructions)
|
¨
|
11
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 93
5.4%
|
12
|
TYPE OF REPORTING PERSON
(see instructions)
IV
|
2 The Reporting Person has delegated all authority
to vote and dispose of shares of common stock of the Issuer owned by it to Evermore Global Advisors, LLC, but has the right to
rescind this authority upon proper notice.
3 This percentage is based on 47,895,050 shares
of common stock outstanding as of December 1, 2020, as set forth in the Issuer’s Form 10-Q for the quarter ended October
31, 2020.
CUSIP NO. 294100102
|
13G
|
Page 4 of 7 Pages
|
Item 1.
Enzo Biochem, Inc.
|
(b)
|
Address of Issuer's Principal Executive Offices.
|
527 Madison Avenue
New York, NY 10022
Item 2.
|
(a)
|
Name of Persons Filing.
|
This Schedule 13G/A is being
jointly filed by Evermore Global Advisors, LLC and Evermore Global Value Fund, a series of Evermore Funds Trust (collectively,
the “Reporting Persons”).
|
(b)
|
Address of Principal Business Office or, if none, Residence.
|
89 Summit Avenue
Summit, NJ 07901
EGA is a Delaware limited liability
company. EGVF is a Massachusetts business trust.
|
(d)
|
Title of Class of Securities.
|
Common Stock – $0.01 par value
294100102
CUSIP NO. 294100102
|
13G
|
Page 5 of 7 Pages
|
Item 3.
|
If this statement is filed pursuant to §240.13d-1(b), or §240.13d-2(b) or (c), check whether the person filing is
a:
|
|
(a)
|
¨
|
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
|
(b)
|
¨
|
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
|
(c)
|
¨
|
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
|
(d)
|
x
|
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
|
(e)
|
x
|
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
|
|
(f)
|
¨
|
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
|
|
(g)
|
¨
|
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
|
|
(h)
|
¨
|
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
|
(i)
|
¨
|
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
|
(j)
|
¨
|
a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
|
|
(k)
|
¨
|
Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:______________
|
The securities reported herein
are beneficially owned by the Evermore Global Value Fund, a series of Evermore Funds Trust (“EGVF”), an investment
company registered under the Investment Company Act of 1940, and other managed account clients of Evermore Global Advisors, LLC
(“EGA”). EGA is an investment adviser registered under the Investment Advisers Act of 1940. Pursuant to the investment
advisory agreements entered into by EGA and each of Evermore Funds Trust (of which EGVF is a series) and its other managed account
clients, sole investment discretion and voting power over the securities held by such persons has been delegated to EGA, although
these agreements and the authority granted to EGA thereunder may be terminated without penalty upon proper notice.
|
(a)
|
Amount Beneficially Owned.
|
EGA – 2,605,607
EGVF – 2,605,607
CUSIP NO. 294100102
|
13G
|
Page 6 of 7 Pages
|
EGA – 5.4%
EGVF – 5.4%
|
(c)
|
Number of shares as to which such person has:
|
|
(i)
|
sole power to vote or to direct the vote:
EGA – 2,605,607
EGVF – 0
|
|
(ii)
|
shared power to vote or to direct the vote:
|
EGA – 0
EGVF – 0
|
(iii)
|
sole power to dispose or to direct the disposition of:
|
EGA – 2,605,607
EGVF – 0
|
(iv)
|
shared power to dispose or to direct the disposition of:
|
EGA – 0
EGVF – 0
Item 5.
|
Ownership of Five Percent or Less of a Class.
|
Not Applicable.
Item 6.
|
Ownership of More than Five Percent on Behalf of Another Person.
|
EGVF and other managed account clients of EGA have the right
to receive or power to direct the receipt of dividends from, as well as proceeds from the sale of, such securities reported herein.
EGVF and other managed account clients of EGA collectively had an interest in 2,605,607 shares, or 5.4%, of the class of securities
reported herein as of December 31, 2020. EGVF had an interest in 2,605,607 shares, or 5.4%, of the class of securities reported
herein as of December 31, 2020. None of EGA’s other managed account clients held any of such securities.
CUSIP NO. 294100102
|
13G
|
Page 7 of 7 Pages
|
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding
Company or Control Person.
|
Not Applicable.
Item 8.
|
Identification and Classification of Members of the Group.
|
Not Applicable.
Item 9.
|
Notice of Dissolution of Group.
|
Not Applicable.
By signing below I certify that, to the best of my knowledge and belief, the securities referred to
above were acquired and are held in the ordinary course of business and were not acquired and are not held for the
purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not
acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true, complete and correct.
|
January
15, 2021
|
|
|
|
Evermore
Global Advisors, LLC
|
|
|
|
By:
|
/s/
Eric LeGoff
|
|
|
Eric
LeGoff
|
|
|
President
|
|
|
|
Evermore
Global Value Fund, a series of Evermore Funds Trust
|
|
|
|
By:
|
/s/
Eric LeGoff
|
|
|
Eric
LeGoff
|
|
|
CEO
|
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jul 2023 to Jul 2024